BridgeBio Pharma, Inc. to Post Q1 2025 Earnings of ($0.93) Per Share, HC Wainwright Forecasts (NASDAQ:BBIO)

BridgeBio Pharma, Inc. (NASDAQ:BBIOFree Report) – Analysts at HC Wainwright upped their Q1 2025 EPS estimates for BridgeBio Pharma in a research report issued on Thursday, May 30th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($0.93) per share for the quarter, up from their previous forecast of ($0.95). HC Wainwright has a “Buy” rating and a $43.00 price objective on the stock. The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($3.20) per share. HC Wainwright also issued estimates for BridgeBio Pharma’s Q2 2025 earnings at ($0.90) EPS, Q3 2025 earnings at ($0.89) EPS, Q4 2025 earnings at ($0.94) EPS and FY2025 earnings at ($3.66) EPS.

Several other research firms have also recently weighed in on BBIO. Evercore ISI began coverage on shares of BridgeBio Pharma in a report on Tuesday, May 14th. They issued an “outperform” rating and a $50.00 price target on the stock. Citigroup raised their price objective on BridgeBio Pharma from $42.00 to $46.00 and gave the company a “buy” rating in a research report on Friday, February 23rd. Raymond James assumed coverage on BridgeBio Pharma in a research report on Thursday, March 21st. They set an “outperform” rating and a $45.00 price objective for the company. JPMorgan Chase & Co. lifted their price target on BridgeBio Pharma from $35.00 to $45.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 20th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $70.00 target price on shares of BridgeBio Pharma in a research report on Tuesday, May 28th. Two research analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $47.62.

Get Our Latest Stock Analysis on BBIO

BridgeBio Pharma Stock Performance

Shares of BridgeBio Pharma stock opened at $28.01 on Monday. BridgeBio Pharma has a 52-week low of $13.26 and a 52-week high of $44.32. The stock has a market capitalization of $5.24 billion, a price-to-earnings ratio of -8.70 and a beta of 1.08. The company’s 50 day moving average price is $27.87 and its 200-day moving average price is $32.11.

BridgeBio Pharma (NASDAQ:BBIOGet Free Report) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.35. The firm had revenue of $211.12 million during the quarter, compared to analysts’ expectations of $140.06 million.

Institutional Trading of BridgeBio Pharma

A number of large investors have recently made changes to their positions in the company. YHB Investment Advisors Inc. acquired a new stake in BridgeBio Pharma during the 1st quarter worth approximately $34,000. Quarry LP acquired a new stake in shares of BridgeBio Pharma in the 4th quarter valued at approximately $50,000. EntryPoint Capital LLC acquired a new stake in shares of BridgeBio Pharma in the 1st quarter valued at approximately $117,000. Assetmark Inc. increased its stake in BridgeBio Pharma by 46.8% in the 4th quarter. Assetmark Inc. now owns 2,931 shares of the company’s stock valued at $118,000 after purchasing an additional 935 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new position in BridgeBio Pharma in the 3rd quarter valued at approximately $132,000. 99.85% of the stock is owned by institutional investors and hedge funds.

BridgeBio Pharma Company Profile

(Get Free Report)

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.

Recommended Stories

Earnings History and Estimates for BridgeBio Pharma (NASDAQ:BBIO)

Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with's FREE daily email newsletter.